Researchers are collecting and storing blood, stool, and urine samples and medical information to better understand Inflammatory Bowel Disease (IBD) to improve disease outcome.

Subjects will be sent a letter detailing the proposed biobank and soliciting enrollment. Following the informed consent process, subjects will provide a blood sample (50 ml), urine sample (50 ml), and stool. The blood and urine samples will either be collected at the one of the Mayo Clinic outpatient laboratories or by a mail-out kit. Subjects will be asked to complete a questionnaire and 24-hour food recall questionnaire (completed online).

Inclusion Criteria:

• Patients diagnosed with inflammatory bowel disease (IBD) who are between the ages of 18 and 85 at time of study enrollment.
• The diagnosis of IBD will be based on the standard IBD criteria including biochemical and colonoscopy screening.
• Women with inflammatory bowel disease of childbearing potential and pregnant women will be offered enrollment because there is no risk to an unborn child in this investigation.
• Patients between the ages of 18 and 85 without history of IBD or colon cancer.

Exclusion Criteria:

• Patients with known liver disease.
• Patients unable to provide informed consent.
• Prisoners and institutionalized individuals.
• Patients with a history of colorectal cancer.

Patients diagnosed with inflammatory bowel disease (IBD) who are between the ages of 18 and 85 at time of study enrollment.

• The diagnosis of IBD will be based on the standard IBD criteria including biochemical and colonoscopy screening.
• Women with inflammatory bowel disease of childbearing potential and pregnant women will be offered enrollment because there is no risk to an unborn child in this investigation.
• Patients between the ages of 18 and 85 without history of IBD or colon cancer.